Evidence map›Paper›PMID 25710463›Full record

ArticlePloS one2015

Fluorescence-guided surgery of retroperitoneal-implanted human fibrosarcoma in nude mice delays or eliminates tumor recurrence and increases survival compared to bright-light surgery.

Fuminari Uehara, Yukihiko Hiroshima, Shinji Miwa, Yasunori Tome, Shuya Yano, Mako Yamamoto, Yasunori Matsumoto, Hiroki Maehara, Kazuhiro Tanaka, Michael Bouvet and 2 more

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Measuring microdose ABY-029 fluorescence signal in a primary human soft-tissue sarcoma resection.Proceedings of SPIE--the International Society for Optical Engineering · 2019
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Fuminari UeharaAntiCancer, Inc., 7917 Ostrow Street, San Diego, California 92111, United States of America; Department of Surgery, University of California San Diego, 200 West Arbor Drive, San Diego, California 92103, United States of America; Department of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0125, Japan.
Yukihiko HiroshimaAntiCancer, Inc., 7917 Ostrow Street, San Diego, California 92111, United States of America; Department of Surgery, University of California San Diego, 200 West Arbor Drive, San Diego, California 92103, United States of America.
Shinji MiwaAntiCancer, Inc., 7917 Ostrow Street, San Diego, California 92111, United States of America; Department of Surgery, University of California San Diego, 200 West Arbor Drive, San Diego, California 92103, United States of America.
Yasunori TomeAntiCancer, Inc., 7917 Ostrow Street, San Diego, California 92111, United States of America; Department of Surgery, University of California San Diego, 200 West Arbor Drive, San Diego, California 92103, United States of America; Department of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0125, Japan.
Shuya YanoAntiCancer, Inc., 7917 Ostrow Street, San Diego, California 92111, United States of America; Department of Surgery, University of California San Diego, 200 West Arbor Drive, San Diego, California 92103, United States of America.
Mako YamamotoAntiCancer, Inc., 7917 Ostrow Street, San Diego, California 92111, United States of America.
Yasunori MatsumotoDepartment of Surgery, University of California San Diego, 200 West Arbor Drive, San Diego, California 92103, United States of America.
Hiroki MaeharaDepartment of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0125, Japan.
Kazuhiro TanakaDepartment of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0125, Japan.
Michael BouvetDepartment of Surgery, University of California San Diego, 200 West Arbor Drive, San Diego, California 92103, United States of America.
Fuminori KanayaDepartment of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0125, Japan.
Robert M HoffmanAntiCancer, Inc., 7917 Ostrow Street, San Diego, California 92111, United States of America; Department of Surgery, University of California San Diego, 200 West Arbor Drive, San Diego, California 92103, United States of America.
University of California, San Diego · USAntiCancer (United States) · USUniversity of the Ryukyus · JP

Funding

Fluorophore-Conjugated Antibodies for Imaging and Resection of GI TumorsR01CA142669 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BOUVET, MICHAEL, YANG, MENG · 2010 to 2015
$1.7M
NCI NIH HHS CA142669NCI NIH HHS R01 CA142669
6 · The paper itself

Abstract

The aim of this study is to determine if fluorescence-guided surgery (FGS) can eradicate human fibrosarcoma growing in the retroperitoneum of nude mice. One week after retroperitoneal implantation of human HT1080 fibrosarcoma cells, expressing green fluorescent protein (GFP) (HT-1080-GFP), in nude mice, bright-light surgery (BLS) was performed on all tumor-bearing mice (n = 22). After BLS, mice were randomized into 2 treatment groups; BLS-only (n = 11) or the combination of BLS + FGS (n = 11). The residual tumors remaining after BLS were resected with FGS using a hand-held portable imaging system under fluorescence navigation. The average residual tumor area after BLS + FGS was significantly smaller than after BLS-only (0.4 ± 0.4 mm(2) and 10.5 ± 2.4 mm(2), respectively; p = 0.006). Five weeks after surgery, the fluorescent-tumor areas of BLS- and BLS + FGS-treated mice were 379 ± 147 mm(2) and 11.7 ± 6.9 mm(2), respectively, indicating that FGS greatly inhibited tumor recurrence compared to BLS. The combination of BLS + FGS significantly decreased fibrosarcoma recurrence compared to BLS-only treated mice (p < 0.001). Mice treated with BLS+FGS had a significantly higher disease-free survival rate than mice treated with BLS-only at five weeks after surgery. These results suggest that combination of BLS + FGS significantly reduced the residual fibrosarcoma volume after BLS and improved disease-free survival.

Indexed as

AnimalsCell Line, TumorFemaleFibrosarcomaFluorescenceGreen Fluorescent ProteinsHumansMiceMice, NudeNeoplasm Recurrence, LocalOptical ImagingRetroperitoneal NeoplasmsSurgery, Computer-AssistedGreen Fluorescent Proteins

Identifiers

PMID25710463
PMCPMC4339719
OpenAlexW1999413645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.